Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | PGR | P06401 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 6/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8859709 | 0.92 | NR3C1 (0.74) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11229266 | 0.91 | NR3C1 (0.66) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11223809 | 0.90 | NR3C1 (0.70) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11228765 | 0.90 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11689579 | 0.89 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11246943 | 0.89 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11813525 | 0.89 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11228768 | 0.89 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL11690649 | 0.89 | NR3C1 (0.69) | NR3C1CYP3A4PGRUSP2LMNA | |
| SCHEMBL6986508 | 0.88 | NR3C1 (0.83) | NR3C1CYP3A4PGRUSP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20220096498-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2022-03-31 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-5145675-A | Polymerizing suspended monomers in presence of porogen to form rigid crosslinked beads with internal pore network, extracting porogen, introducing active substance | ADVANCED POLYMER SYSTEMS, INC. (US) | 1992-09-08 | — | — | US | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | FORDOZ PHARMA CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-4962133-A | PRECIPITATION POLYMERIZATION; CONTROLLING PARTICLE SIZE BY VARYING RATE OF STIRRING | DOW CORNING CORPORATION (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0277211-A4 | POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE | — | 1990-09-05 | — | — | EP | disclosed |
| EP-0277211-A1 | POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE. | ADVANCED POLYMER SYSTEMS INC (US) | 1988-08-10 | — | — | EP | disclosed |
| WO-1988001164-A1 | POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE | ADVANCED POLYMER SYSTEMS, INC. (US) | 1988-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | NR3C1 4364/4885CYP3A4 2902/4885PGR 157/4885 |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | IL1B, TNF, MIF | NR3C1 25/4885CYP3A4 1290/4885PGR 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.